Comparison of Pharmacokinetics of the GalNAc-Conjugated Antisense Oligonucleotide GSK3389404 in Participants with Chronic Hepatitis B Infection across the Asia-Pacific Region.


Journal

Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061

Informations de publication

Date de publication:
24 01 2023
Historique:
pubmed: 13 12 2022
medline: 27 1 2023
entrez: 12 12 2022
Statut: ppublish

Résumé

GSK3389404, an N-acetyl galactosamine-conjugated antisense oligonucleotide (ASO), was in clinical development for chronic hepatitis B (CHB) treatment. Few studies have examined ASOs in Asian participants. In this analysis, the plasma pharmacokinetics (PK) of GSK3389404 were characterized and compared in patients with CHB across the Asia-Pacific region (N = 64), including mainland China (

Identifiants

pubmed: 36507675
doi: 10.1128/aac.00900-22
pmc: PMC9872700
doi:

Substances chimiques

Oligonucleotides, Antisense 0

Types de publication

Randomized Controlled Trial Multicenter Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0090022

Références

Nucleic Acid Ther. 2019 Feb;29(1):16-32
pubmed: 30570431
Adv Drug Deliv Rev. 2015 Jun 29;87:46-51
pubmed: 25666165
Nucleic Acid Ther. 2016 Apr;26(2):111-7
pubmed: 26959999
Nat Med. 2021 Oct;27(10):1725-1734
pubmed: 34642494
Perspect Clin Res. 2011 Oct;2(4):121-3
pubmed: 22145121
Ther Innov Regul Sci. 2014 May;48(3):393-403
pubmed: 30235544
J Clin Med. 2020 Oct 01;9(10):
pubmed: 33019573
Drug Discov Today. 2020 Mar;25(3):491-496
pubmed: 31926136
Lancet. 2016 Nov 5;388(10057):2239-2253
pubmed: 27665230
Mol Ther Nucleic Acids. 2017 Mar 17;6:116-132
pubmed: 28325278
Drug Metab Dispos. 2003 Nov;31(11):1419-28
pubmed: 14570775
J Hepatol. 2017 Aug;67(2):370-398
pubmed: 28427875
Clin Pharmacol Drug Dev. 2022 Oct;11(10):1191-1202
pubmed: 35971951
Clin Pharmacol Ther. 2008 Sep;84(3):347-61
pubmed: 18231117
Nucleic Acids Res. 2014 Jul;42(13):8796-807
pubmed: 24992960
Expert Opin Drug Metab Toxicol. 2009 Apr;5(4):381-91
pubmed: 19379126
BMC Infect Dis. 2019 Sep 18;19(1):811
pubmed: 31533643
Clin Pharmacol Drug Dev. 2019 Aug;8(6):790-801
pubmed: 30861337
J Hepatol. 2022 Oct;77(4):967-977
pubmed: 35714812
Nucleic Acid Ther. 2019 Apr;29(2):82-91
pubmed: 30817230

Auteurs

Kelong Han (K)

GSK, Collegeville, Pennsylvania, USA.

Hiroshi Ito (H)

GSK K.K., Tokyo, Japan.

Robert Elston (R)

GSK, Stevenage, United Kingdom.

Jennifer Cremer (J)

GSK, Durham, North Carolina, USA.

Steve Hood (S)

GSK, Stevenage, United Kingdom.

Melanie Paff (M)

GSK, Collegeville, Pennsylvania, USA.

Dickens Theodore (D)

GSK, Durham, North Carolina, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH